tbuckley/cabot-search huggingface dataset:
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
Authors: V S Hoffmann, M Baccarani, J Hasford, F Castagnetti, F Di Raimondo, L F Casado, A Turkina, D Zackova, G Ossenkoppele, A Zaritskey, M Höglund, B Simonsson, K Indrak, Z Sninska, T Sacha, R Clark, A Bogdanovic, A Hellmann, L Griskevicius, G Schubert-Fritschle, D Sertic, J Guilhot, S Lejniece, I Zupan, S Burgstaller, P Koskenvesa, H Everaus, P Costeas, D Lindoerfer, G Rosti, S Saussele, A Hochhaus, R Hehlmann
Journal: Leukemia (2016)
Disclosure of Medical Error
Authors: Wendy Levinson, Jensen Yeung, Shiphra Ginsburg
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P1318 : Phase I dose escalation study of the safety, immunoregulatory activity, pharmacokinetics, and preliminary antitumor activity of nivolumab in advanced hepatocellular carcinoma in patients with or without chronic viral hepatitis
Authors: B. Sangro, A.B. El-Khoueiry, T.S. Crocenzi, T.H. Welling, W. Feely, J.A. Anderson, C. dela Cruz, I. Melero
Journal: Journal of Hepatology (2015)
Bevacizumab alone or with chemotherapy in highly pretreated, relapsed, epithelial ovarian cancer patients.
Authors: B. Ojeda, A. Casado, A. Tibau, A. Redondo, M. Beltran, E. Garcia-Martinez, A. Santaballa, B. Pardo, P. Lianes, I. Bover, J. Garcia-Donas, C. M. Churruca, J. F. Cueva, A. B. Sanchez-Heras, M. M. Gordon-Santiago, A. Arcusa Lanza, A. Lopez-Rodriguez, C. Caballero, M. E. Ortega-Izquierdo, A. González-Martín
Journal: Journal of Clinical Oncology (2011)

e15590
Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction
Authors: Lynn A. Beer, Andrew V. Kossenkov, Qin Liu, Eline Luning Prak, Susan Domchek, David W. Speicher, Bonnie Ky
Journal: Circulation Research (2016)

Rationale: There is a critical need to develop robust, mechanistic strategies to identify patients at increased risk of cancer therapeutics–related cardiac dysfunction (CTRCD). Objective: We aimed to discover new biomarkers associated with doxorubicin- and trastuzumab-induced CTRCD using high-throughput proteomic profiling. Methods and Results: Plasma, echocardiograms, and clinical outcomes were collected at standardized intervals in breast cancer patients undergoing doxorubicin and trastuzumab cancer therapy. Thirty-one longitudinal plasma samples from 3 cases with CTRCD and 4 age- and cancer-matched controls without CTRCD were processed and analyzed using label-free liquid chromatography–mass spectrometry. From these analyses, 862 proteins were identified from case/control pairs 1 and 2 and 1360 proteins from case/control pair 3. Proteins with a &gt;1.5-fold change in cases compared with controls with a P &lt;0.05 either at the time of CTRCD diagnosis or across all time points were considered candidate diagnostic or predictive biomarkers, respectively. The protein that demonstrated the largest differences between cases and controls was immunoglobulin E, with higher levels detected at baseline and across all time points in controls without CTRCD as compared with matched CTRCD cases ( P &lt;0.05). Similarly, in a validation study of 35 participants treated with doxorubicin and trastuzumab, high baseline immunoglobulin E levels were associated with a significantly lower risk of CTRCD ( P =0.018). Conclusions: In patients receiving doxorubicin and trastuzumab, high baseline immunoglobulin E levels are associated with a lower risk of CTRCD. These novel findings suggest a new paradigm in cardio-oncology, implicating the immune system as a potential mediator of doxorubicin- and trastuzumab-induced cardiac dysfunction.
Predictive factors for the severity of congestive heart failure after an epirubicin-based treatment for metastatic breast cancer.
Authors: M. Ryberg, D. L. Nielsen, M. T. Jensen, G. Nielsen, P. K. Andersen
Journal: Journal of Clinical Oncology (2010)

1124 Background: Patients treated with anthracyclines have a well described risk for developing congestive heart failure (CHF). However, little is known about possible predictive factors for the severity of the CHF acquired. Methods: 125 patients who developed CHF class ≥ II according to New York Heart Association (NYHA) guidelines were included in this retrospective study. The patients were recruited consecutively from 1,097 patients with metastatic breast cancer admitted to Herlev Hospital from November 1983 through November 2003 for an epirubicin-based chemotherapy. No patients treated had a history of cardiac disease before start of epirubicin. Statistics: Univariate analysis based on ordinal logistic regression with NYHA class at time of cardiac disease as the outcome. Results: The median time after cessation of epirubicin to onset of CHF was 3 months (range 0.01 to 66.7 months). The median survival was 7.3 months (range 0.01 to +121.1 months), with eights patients (6.4%) still alive. The distribution of patients in the NYHA class II, III, IV and class ≥ II was: 35 patients (28%), 38 patients (30.4%), 39 patients (31.2%), and 13 patients (10.4%), respectively. Following variables were tested in the univariate analysis: cumulative dose of epirubicin mg/m2, age at the time of epirubicin treatment, previous antihormonal treatment or mediastinal irradiation, and comorbidity with disposition to heart disease. Variables there all previously had been demonstrated as a risk factor for developing CHF after an epirubicin treatment. Moreover, the time from the cessation of epirubicin treatment to the onset of cardiotoxicity and the value of serum-lactatdehydrogenase at the onset of the CHF were included. None of these variables became significant, even at a level of 0.20. Conclusions: No predictive factor for the degree of congestive heart failure (NYHA class) was identified in patients with heart failure due to an epirubicin treatment. Even cumulative epirubicin dose mg/m2, age, comorbidity with disposition to heart disease, or previous mediastinal irradiation had an influence of its own. No significant financial relationships to disclose.
Oily fish intake reduces risk of diabetic retinopathy, study shows
Authors: Susan Mayor
Journal: BMJ (2016)

Older patients with type 2 diabetes who consume dietary omega 3 fatty acids equivalent to at least two weekly servings of oily fish have a significantly lower risk of sight threatening diabetic retinopathy than those who eat less, a prospective observational study has shown.1

Diabetic retinopathy is a major cause of vision loss in older people. The pathogenesis is not fully understood, but inflammation, oxidative stress, and microvascular changes play important roles in worsening …
Physicians as Citizens
Authors: Matthew K Wynia, Chalmers C Clark
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cutaneous toxicity in erlotinib treatment for advanced non-small cell lung cancer (NSCLC).
Authors: R. Bernabée, M. Cobo, I. Barneto, J. Valdivia, I. Fernandez, A. Rueda, R. Villatoro, L. de la Curz
Journal: Journal of Clinical Oncology (2010)

e18026 Background: We conducted this prospective study to evaluate the correlation between efficacy and toxicity of the therapy of erlotinib in advanced NSCLC patients (pts). Methods: Eligibility criteria: advanced NSCLC, Performance status (PS) 0-2, adequate renal, hepatic and bone marrow function. Treatment consisted on: erlotinib 150 mg/day until progression or unacceptable toxicity. Safety was evaluated monthly and tumor evaluation was performed bimonthly. Results: 210 pts were enrolled, 190 (90.5%) stage IV and 20 (9.5%) wet stage IIIB, all valid for response and toxicity. The median age was 63 years (range: 34-89) with 153 (72.9%) males and 57 (27.1%) females. 33 pts (15.7%) were treated with erlotinib in first line, and 167 pts (84.3%) in succesives lines: recived prior chemotherapy for NSCLC: 143 pts (68.1%) one CT regimen and 34 pts (16.2%) 2 or more CT regimen. Histology subtypes: adenocarcinoma 147 pts (70%), bronquioloalveolar 2 pts (1%), large cell 15pts (7.1%) and squamous 40 pts (19%). Respect PS: 0 was in 64 pts (30.8%), PS 1 in 91 pts (43.8%), and PS 2 in 53 (25.2%). Efficacy: Erlotinib improved response in 37 pts (18%), in 96 pts (46.6) prolonged stabilization, and 73 pts (35.4%) had progression. The median free progession survival (PFS) and overall survival (OS) were 4 months (m) (95% CI, 3.1-4.3), and 6.9 m (95% CI, 5,9-7,7) respectively. Toxicity: The most frequent side effect was skin rash: 129 pats (61.7%), grade (g) 1 in 57 pts (27.14%), g 2 in 50 pts (23.8%) and g 3 in 22 pts (10.47%). Only 2 pts (0.95%) had diarrea g 3, and 1 pt had asthenia g3, and no other significant side effects were observed. Efficacy according rash: We defined two differents groups respect grade of rash to compare efficacy: 72 (34.4%) pts had rash ≥ 2 and 137 (65.6%) pats had rash < 2. We found significant differences in PFS according to rash grade experimented by pats: rash 66 pts (91.7%) with rash ≥ 2, p < 0.001. Conclusions: This prospective study shows Erlotinib Efficacy and Safety in the treatment of NSCLC pts. Pts who developed rash ≥ 2 had a great benefit in terms of PFS, OS, OR and Clinical Benefit, according to previous retrospective data published. No significant financial relationships to disclose.
Lancement d’une formation nationale à l’épidémiologie de terrain en France
Authors: B Helynck
Journal: Eurosurveillance (2002)

La formation a l’epidemiologie d’intervention et a l’evaluation des risques sanitaires est un element crucial de la constitution du reseau de partenaires de l’InVS (services de l’Etat, agences, institutions...). Une culture commune et des modes d’intervention coherents sont necessaires aux differents acteurs de la veille sanitaire afin d’optimiser la performance des dispositifs de surveillance et de reponses aux alertes. C’est pourquoi l’InVS et l’Ecole nationale de la sante publique (ENSP) se sont engages depuis plusieurs annees conjointement dans le processus de creation d’un programme national de formation.
Identification of a Gene Expression Signature Characterizing Clonal Fitness and Dominance in Vivo in a Murine Model of MLL-AF9 Leukemia
Authors: Francois Mercier, Jiantao Shi, David Sykes, Youmna Sami Kfoury, Rushdia Z. Yusuf, Elizabeth Miller, Radovan Vasic, Alex Zhu, Franziska Michor, Winston Hide, David T. Scadden
Journal: Blood (2014)
Non Myeloablative Allogeneic Related Transplant in Patients with Aggressive B Cell Lymphoma: Results of Two Multicenter Spanish Trials. The GELTAMO Group.
Authors: M.D. Caballero, J. Briones, M.V Mateos, J.F. Tomás, R. Martino, J. de la Serna, J.L. Díez, J.A. Pérez-Simón, A. Sureda, J. Sarrá, J. García-Laraña, J.M. Ribera, J. Sierra, J.F. San Miguel
Journal: Blood (2007)
Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model
Authors: Leena Hilakivi-Clarke, Anni Wärri, Kerrie B. Bouker, Xiyuan Zhang, Katherine L. Cook, Lu Jin, Alan Zwart, Nguyen Nguyen, Rong Hu, M. Idalia Cruz, Sonia de Assis, Xiao Wang, Jason Xuan, Yue Wang, Bryan Wehrenberg, Robert Clarke
Journal: JNCI Journal of the National Cancer Institute (2016)

Responses to endocrine therapies vary among patients with estrogen receptor (ER+) breast cancer. We studied whether in utero exposure to endocrine-disrupting compounds might explain these variations.We describe a novel ER+ breast cancer model to study de novo and acquired tamoxifen (TAM) resistance. Pregnant Sprague Dawley rats were exposed to 0 or 0.1 ppm ethinyl estradiol (EE2), and the response of 9,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors to 15 mg/kg TAM, with (n = 17 tumors in the controls and n = 20 tumors in EE2 offspring) or without 1.2 g/kg valproic acid and 5 mg/kg hydralazine (n = 24 tumors in the controls and n = 32 tumors in EE2 offspring) in the female offspring, was assessed. One-sided Chi2 tests were used to calculate P values. Comparisons of differentially expressed genes between mammary tumors in in utero EE2-exposed and control rats, and between anti-estrogen-resistant LCC9 and -sensitive LCC1 human breast cancer cells, were also performed.In our preclinical model, 54.2% of mammary tumors in the control rats exhibited a complete response to TAM, of which 23.1% acquired resistance with continued anti-estrogen treatment and recurred. Mammary tumors in the EE2 offspring were statistically significantly less likely to respond to TAM (P = .047) and recur (P = .007). In the EE2 offspring, but not in controls, adding valproic acid and hydralazine to TAM prevented recurrence (P < .001). Three downregulated and hypermethylated genes (KLF4, LGALS3, MICB) and one upregulated gene (ETV4) were identified in EE2 tumors and LCC9 breast cancer cells, and valproic acid and hydralazine normalized the altered expression of all four genes.Resistance to TAM may be preprogrammed by in utero exposure to high estrogen levels and mediated through reversible epigenetic alterations in genes associated with epithelial-mesenchymal transition and tumor immune responses.
Effect of computerized physician order entry (CPOE) on chemotherapy prescribing error.
Authors: R. Stein, S. Cheesman, D. Blake, N. Saini, T. Cave, G. Pang, B. Bagnall, J. Bradley
Journal: Journal of Clinical Oncology (2010)

6034 Background: CPOE systems have previously been reported to reduce prescription error. There are few studies of CPOE in oncology practice. We studied the effect of replacing manual prescribing (MP) by a specialized chemotherapy CPOE system, ChemoCare, on prescribing error in a hematology-oncology practice in a comprehensive cancer center. Methods: All errors made during a 12-week period prior to CPOE implementation detected at routine pre-treatment pharmacy checks were categorized according to error type, and were scored for severity using the U.K. National Patient Safety Agency risk matrix by a panel of 4 blinded adjudicators (2 pharmacists and 2 doctors) working independently of each other; conflicts were resolved by a fifth adjudicator. Errors involving chemotherapy and supportive care with the exception of anti-infectives were analyzed. An identical exercise was conducted 15 months later, 6 months following completion of CPOE implementation. Results: A total of 49 of 251 (19.5%) of MP prescriptions contained an error compared to 14 of 272 (5.2%) of CPOE prescriptions, a 73% reduction (2p<0.0001, chi squared). The number of errors judged as major or potentially catastrophic fell by 50% whilst those of moderate severity fell by 81% with the use of CPOE (table). The drug dose error-rate was reduced by 74%, from 7.2% to 1.8% of prescriptions (2p=0.003), with a similar fall in error involving prescribing the wrong drug or wrong number of drug doses. There was a change in the nature of errors made with CPOE prescribing with 50% (7) arising from incorrect use of the system. These included 4 cases of zero drug doses arising from a failure to enter height and weight data. Conclusions: CPOE prescribing of chemotherapy offers a substantial improvement in patient safety. Error severity Catastrophic Major Moderate Minor None Total MP CPOE MP CPOE MP CPOE MP CPOE MP CPOE MP CPOE Wrong regimen 0 0 1 1 0 0 0 0 0 0 1 1 Wrong dose 1 0 6 2 10 3 0 0 1 0 18 5 Wrong number of doses 0 0 3 1 1 0 1 0 0 0 5 1 Missing or wrong drug 0 0 0 2 2 0 3 0 1 0 6 2 Supportive care error 0 0 0 0 4 1 5 4 3 0 12 5 Miscellaneous 0 0 1 0 4 0 2 0 0 0 7 0 Total 1 0 11 6 21 4 11 4 5 0 49 14 No significant financial relationships to disclose.
Paracrine nitric oxide induces expression of cardiac sarcomeric proteins in adult progenitor cells through soluble guanylyl cyclase/cyclic-guanosine monophosphate and Wnt/β-catenin inhibition
Authors: Aurelia De Pauw, Paul Massion, Belaid Sekkali, Emilie Andre, Caroline Dubroca, Jana Kmecova, Caroline Bouzin, Ann Friart, Catherine Sibille, Patrick Gilon, Delphine De Mulder, Hrag Esfahani, Adrien Strapart, Ruben Martherus, Valéry Payen, Pierre Sonveaux, Peter Brouckaert, Stefan Janssens, Jean-Luc Balligand
Journal: Cardiovascular Research (2016)

Cardiac progenitor cells (CPC) from adult hearts can differentiate to several cell types composing the myocardium but the underlying molecular pathways are poorly characterized. We examined the role of paracrine nitric oxide (NO) in the specification of CPC to the cardiac lineage, particularly through its inhibition of the canonical Wnt/ β -catenin pathway, a critical step preceding cardiac differentiation. Sca1 + CPC from adult mouse hearts were isolated by magnetic-activated cell sorting and clonally expanded. Pharmacologic NO donors increased their expression of cardiac myocyte-specific sarcomeric proteins in a concentration and time-dependent manner. The optimal time window for NO efficacy coincided with up-regulation of CPC expression of Gucy1a3 (coding the alpha1 subunit of guanylyl cyclase). The effect of paracrine NO was reproduced in vitro upon co-culture of CPC with cardiac myocytes expressing a transgenic NOS3 (endothelial nitric oxide synthase) and in vivo upon injection of CPC in infarcted hearts from cardiac-specific NOS3 transgenic mice. In mono- and co-cultures, this effect was abrogated upon inhibition of soluble guanylyl cyclase or nitric oxide synthase, and was lost in CPC genetically deficient in Gucy1a3 . Mechanistically, NO inhibits the constitutive activity of the canonical Wnt/ β -catenin in CPC and in cell reporter assays in a guanylyl cyclase-dependent fashion. This was paralleled with decreased expression of β -catenin and down-regulation of Wnt target genes in CPC and abrogated in CPC with a stabilized, non-inhibitable β -catenin. Exogenous or paracrine sources of NO promote the specification towards the myocyte lineage and expression of cardiac sarcomeric proteins of adult CPC. This is contingent upon the expression and activity of the alpha1 subunit of guanylyl cyclase in CPC that is necessary for NO-mediated inhibition of the canonical Wnt/ β -catenin pathway.
Australia’s torture of asylum seekers
Authors: David Berger
Journal: BMJ (2016)

It’s time for doctors to march

The Guardian newspaper’s publication of 8000 leaked pages alleging horrendous abuse and appalling conditions for detainees at Australia’s immigration detention centre on the Pacific island of Nauru has again brought Australia’s treatment of indefinitely imprisoned asylum seekers into sharp public focus.1

The so-called Nauru files, published on 10 August, describe alleged assaults, sexual abuse, self harm attempts, and child abuse. The Guardian ’s analysis showed 51.3% of the 2116 reports involve children, although children were only about 18% of those in detention at the time.

Doctors’ leaders in Australia, including Michael Gannon, president of the Australian Medical Association, have again roundly condemned the alleged treatment revealed. But the response of the country’s immigration minister, Peter Dutton, has been to trivialise and dismiss the reports, even accusing asylum seekers of self immolation in their attempts to get to Australia.2 3

Advocates of humane treatment for asylum seekers are left once more scratching their heads and wondering how …
Outbreak of Serogroup C Meningococcal Disease Primarily Affecting Men Who Have Sex with Men — Southern California, 2016
Authors: Srinivas Nanduri, Chelsea Foo, Van Ngo, Claire Jarashow, Rachel Civen, Ben Schwartz, John Holguin, Eric Shearer, Matt Zahn, Kathleen Harriman, Kathleen Winter, Cecilia Kretz, How Yi Chang, Sarah Meyer, Jessica MacNeil
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

During March 4-August 11, 2016, 25 outbreak-associated cases of meningococcal disease, including two deaths (8% case-fatality ratio), were reported in Southern California. Twenty-four of the cases were caused by serogroup C Neisseria meningitidis (NmC) and one by N. meningitidis with an undetermined serogroup (Figure). On June 24, 2016, in response to this increase in NmC cases, primarily among men who have sex with men (MSM) in Los Angeles County, the city of Long Beach, and Orange County, the California Department of Public Health (CDPH) issued a press release and health advisory, declaring an outbreak of NmC in Southern California (1).
BARs (B -cell receptor a ntigens for r everse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms
Authors: Michael Pfreundschuh, Lorenz Thurner, Stefan Barth, Diana Pickert, Natalie Fadle, Maria Kemele, Evi Regitz, Frank Neumann, Thomas Nachreiner, Klaus-Dieter Preuss
Journal: Blood (2015)